GPMDB00234OtherNaba A, et al.InstrumentNot AvailableNot availableHomo_sapiens_viruses,mus_musculus_viruses, Human_female,mouse_femaleNot available24618895http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002368http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002357http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002367http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002356http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002359http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002348http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002347http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002369http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002349http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002360http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002351http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002362http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002361http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002350http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002364http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002353http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002363http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002366http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002355http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002354http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002365David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of TechnologyNot availableGPMDBThe extracellular matrix (ECM) is a major component of tumors and a significant contributor to cancer progression. In this study, we use proteomics to investigate the ECM of human mammary carcinoma xenografts and show that primary tumors of differing metastatic potential differ in ECM composition. Both tumor cells and stromal cells contribute to the tumor matrix and tumors of differing metastatic ability differ in both tumor- and stroma-derived ECM components. We define ECM signatures of poorly and highly metastatic mammary carcinomas and these signatures reveal up-regulation of signaling pathways including TGFβ and VEGF. We further demonstrate that several proteins characteristic of highly metastatic tumors (LTBP3, SNED1, EGLN1, and S100A2) play causal roles in metastasis, albeit at different steps. Finally we show that high expression of LTBP3 and SNED1 correlates with poor outcome for ER(-)/PR(-)breast cancer patients. This study thus identifies novel biomarkers that may serve as prognostic and diagnostic tools. DOI: http://dx.doi.org/10.7554/eLife.01308.001.Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.Naba Alexandra A,Clauser Karl R KR,Lamar John M JM,Carr Steven A SA,Hynes Richard O RO,Naba Alexandra A, Clauser Karl R KR, Lamar John M JM, Carr Steven A SA, Hynes Richard O ROCarcinomas, Mammary Neoplasms, Human Mammary Neoplasm, Carcinoma, Carcinoma of breast NOS, Breast Neoplasm, Human Mammary, Metastasis, Metastases., Breast Neoplasms, NEOPL BREAST, Mammary Neoplasm, Carcinoma of breast NOS (disorder), Neoplasms, Mammary Carcinoma, Metastases, carcinoma OF breast, Human Mammary Carcinomas, Matrix, Human Mammary Neoplasms, Neoplasm Metastases, Tumor, Matrices, Cancer of the Breast, Human, CA - Carcinoma of breast, Mammary Carcinomas, Breast Tumor, BREAST NEOPL, Extracellular, Breast Tumors, Breast Cancer, Neoplasm, Carcinoma of breast (disorder), Human Mammary Carcinoma, Cancer of Breast, Carcinoma of the Breast, Extracellular Matrices, Breast, Mammary carcinoma, proteinaceous extracellular matrix, Tumors, CancerHuman Mammary Neoplasm, Carcinoma, data, Carcinoma of breast NOS, use, IRF-1, Stromal, Breast Neoplasms, Heterograft, Neoplasms, Human Mammary Neoplasms, TRANSPL HETEROL, Tumor, compositionality, Transplantations, composed of, tumours, Cell, EMILIN4, heterologous transplantation, NEOPL, Human, Experiment, XENOTRANSPL, Mammary Carcinomas, Breast Tumor, BREAST NEOPL, Stromal Cell, Neoplasm, Human Mammary Carcinoma, Carcinoma of the Breast, Mammary carcinoma, Heterologous Transplantations, MAR, Carcinomas, study, Mammary Neoplasms, Xenograft, Breast Neoplasm, Human Mammary, Xenotransplantation, Transplantation, NEOPL BREAST, Mammary Neoplasm, Carcinoma of breast NOS (disorder), content, Mammary Carcinoma, carcinoma OF breast, Human Mammary Carcinomas, Heterografts, HETEROL TRANSPL, composition, tumour, Xenografts, Cancer of the Breast, CA - Carcinoma of breast, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), metastatic, GPIa*, Xenotransplantations, Breast Tumors, Breast Cancer, ECM, structure, Cells, Carcinoma of breast (disorder), Cancer of Breast, MMRN, Breast, NEOPLASMS BENIGN, Neoplastic Growth, Neoplasia, Heterologous, stromal connective tissue, MDA-MB-231, EMILIN4., Tumors, CancerCarcinomas, Mammary Neoplasms, Human Mammary Neoplasm, Carcinoma, Carcinoma of breast NOS, Breast Neoplasm, Human Mammary, Metastasis, Metastases., Breast Neoplasms, NEOPL BREAST, Mammary Neoplasm, Carcinoma of breast NOS (disorder), Neoplasms, Mammary Carcinoma, Metastases, carcinoma OF breast, Human Mammary Carcinomas, Matrix, Human Mammary Neoplasms, Neoplasm Metastases, Tumor, Matrices, Cancer of the Breast, Human, CA - Carcinoma of breast, Mammary Carcinomas, Breast Tumor, BREAST NEOPL, Extracellular, Breast Tumors, Breast Cancer, Neoplasm, Carcinoma of breast (disorder), Human Mammary Carcinoma, Cancer of Breast, Carcinoma of the Breast, Extracellular Matrices, Breast, Mammary carcinoma, proteinaceous extracellular matrix, Tumors, CancerZMYND6, Hif-p4h-2, Viral Marker, Biological Markers, Surrogate Endpoints, Metastasis, Laboratory, Breast Neoplasms, Heterograft, Gpi1s., Biochemical, Endpoint, Human Mammary Neoplasms, CAN19, Neoplasm Metastases, TRANSPL HETEROL, Tumor, Serum, composed of, MSPKA, SM-20, Laboratory Markers, Biological, Extracellular Matrices, GD-VEGF, Gpi-1, SM20, Snep, BC, Mammary Neoplasms, PHD2, Phd2, AI503754, Nlk, Human Mammary Carcinomas, composition, proteins, ORF13, CA - Carcinoma of breast, 6720455I24Rik, Immune, GPIa*, Xenotransplantations, Markers, Viral Markers, Carcinoma of breast (disorder), Vascular Endothelial Growth Factor-A, Tumors, Gpi, Carcinoma, C1orf12, Viral, Surrogate Endpoint, Up-Regulation (Physiology), Biochemical Markers, SST3, Biologic Marker, tumours, Glioma-Derived Vascular Endothelial Cell Growth Factor, AI642697, mOC-X, Playthings and Play, Marker, VEGF-A, Plaything, NK|GPI, HIFPH2, Mammary carcinoma, Heterologous Transplantations, Carcinomas, Xenograft, Org, ORG, Xenotransplantation, End Points, Transplantation, NEOPL BREAST, Upregulation, VPF, Vpf, content, carcinoma OF breast, Toys, Gpi1-r, Gpi1-s, Xenografts, Immunologic, Laboratory Marker, Gpi1-t, D430044C15Rik, GLC3D, pp6425, metastatic, Patient, Biochemical Marker, Breast Tumors, Cells, ECYT3, Vascular Endothelial Growth Factor, Glioma Derived Vascular Endothelial Cell Growth Factor, Vasculotropin, Bglap-rs1, Carcinoma of breast NOS, Plays, MSTP031, STHAG6, Stromal, Clinical Markers, AI461847, Clinical Marker, Neoplasms, Matrix, Gene, Matrices, Transplantations, NEOPL, heterologous transplantation, DOI, Human, Vascular Permeability Factor, Surrogate End Points, Surrogate Markers, Breast Tumor, Vascular, BREAST NEOPL, Stromal Cell, Gene Products, Pgi, Carcinoma of the Breast, malignant tumour, VEGF164, Toy, doi, study, Permeability Factor, Human Mammary, Clinical, LTBP2, Playthings, LTBP3, Mammary Neoplasm, Receptor Up-Regulation, Gpi-1r, Carcinoma of breast NOS (disorder), Gpi-1s, Mammary Carcinoma, Up Regulation, Biological Marker, Phi, Gpi-1t, malignant neoplasia, Heterografts, tumour, Cancer of the Breast, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS), Immunologic Markers, Puppets, Clients, Extracellular, ECM, Play, C14orf141, Breast, PHD-2, Immunologic Marker, Neoplastic Growth, Heterologous, Puppet, Biologic, Cancer, Human Mammary Neoplasm, AI197264, use, Malignant Neoplasm, Metastases, Proteins, HIF-PH2, Serum Markers, LTBP-3, End Point, compositionality, MF, Amf, Client, Cell, EMILIN4, Immune Marker, polypeptide, XENOTRANSPL, Mammary Carcinomas, Surrogate End Point, Protein, Neoplasm, Human Mammary Carcinoma, NK, WMS3, Biologic Markers, MVCD1, Breast Neoplasm, Serum Marker, Vegf, Surrogate, HALAH, Endpoints, HPH2, HETEROL TRANSPL, Cancers, malignant tumor, Surrogate Marker, Protein Gene Products, Gene Proteins, IRE-BP1, VEGF, S100L, Breast Cancer, structure, Cancer of Breast, MMRN, HPH-2, NEOPLASMS BENIGN, Neoplasia, proteinaceous extracellular matrix, stromal connective tissue, Immune Markers2304http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320002348dbgap_ncbi~0patentfamilies~0rfam~0merops~0complex-portal~0uniprot~0wormbaseparasite~0embl-covid19~0reactome~0emdb~0wgs_masters~0ebiweb_resources~0opentargets_genetics~0biomodels_all~0ipd-mhc~0ebiweb_teams~0taxonomy~0genome_assembly~0sc-experiments~0ebiweb_people~0enzymeportal_enzymes~0ipd-nhkir~0cellosaurus~0pdbe~0chebi~0patentproteins~0interpro7~0uniref~0chembl~0pdbekb~0gpcrdb~0hgnc~0sc-genes~0intact~0rhea~0ebiweb_training~0alphafold~0imgt-hla~0patentnucleotides~0ensemblroot~0eva_studies~0non-coding~0europepmc~0pubmed~1identifiers_registry~0pdbechem~0massive~1hpa-covid19~0eva-variants-covid19~0biosamples~0gwas_catalog~0biotools~0tls_masters~0mesh~0coding~0sra~0opentargets~0efo~0embl-pathogen~0project~0human_diseases~0geo_datasets~0embl~0treefam~0uniparc~0ols~0dgva~0intenz~0go~0tsa_masters~0biosamples-covid19~0ebiweb_corporate~0omim~0lrg~0earlycause-molecular-sequences~0ipd-kir~0empiar~0rnacentral~0orcid_data_claims~0gpmdb~2lineage-covid19~0metagenomics~0pfam~0varsite~00Resource Reanalysis0.00.00.0070943861813695250.01.0falseExtracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.Data from Massive, MSV000078535. MDAMB23 experiment: D101003_MDAMB231_1_OGE, file: D101003_MDAMB231_1_OGE02_rafkt_ft8_cc_01.mzml. Published as part of Elife. 2014 Mar 11;3:e01308 . From the Abstract: {{i}} In this study, we use proteomics to investigate the ECM of human mammary carcinoma xenografts and show that primary tumors of differing metastatic potential differ in ECM composition. Both tumor cells and stromal cells contribute to the tumor matrix and tumors of differing metastatic ability differ in both tumor- and stroma-derived ECM components. {{/i}}2014-08-19GPM3232000234824618895MSV000078535